Patent ID: 7351721
Filing Date: 2008-04-01
Classification: A61K,A61P,C07B,C07C,C07D,C07K

Abstract:
1. An amino acid compound of formula (I) wherein, R wherein all the said phenyl and C3-8 cycloalkyl in R A is —CO—, R D is C1-4 alkylene, E is —O—, —S—, —SO—, or —SO R wherein the carbocyclic ring in R J is J J J R R R R M is carbocyclic ring or heterocyclic ring which may be substituted with 1-3 substituent(s) (with the proviso that when the carbocyclic ring of said carbocyclic ring or heterocyclic ring which may be substituted with 1-3 substituent(s) is phenyl, said ring is substituted with at least one substituent(s), and that when the said heterocyclic ring of said carbocyclic ring or heterocyclic ring which may be substituted with 1-3 substituent(s) is 5-7-membered saturated heterocyclic ring in which the nitrogen atom in the said heterocyclic ring is bonded to group L shown as and which may contain further one nitrogen atom or one oxygen atom, then such a ring is substituted with at least one substituent(s)), C1-4 alkyl substituted with 1-2 substituent(s) selected from the group consisting of carbocyclic ring which may be substituted with 1-3 substituent(s), and heterocyclic ring which may be substituted with 1-3 substituent(s), —O-(carbocyclic ring or heterocyclic ring which may be substituted with 1-3 substituent(s)) (with the proviso that when the carbocyclic ring of said —O-(carbocyclic ring or heterocyclic ring which may be substituted with 1-3 substituent(s) is phenyl, said ring is substituted with at least one substituent(s)), —S-(carbocyclic ring or heterocyclic ring which may be substituted with 1-3 of substituent(s)), —NR 38 -(carbocyclic ring or heterocyclic ring which may be substituted with 1-3 of substituent(s)) in which R 38 is hydrogen or C1-4 alkyl which may be substituted with one phenyl, —O—CH 2 -(carbocyclic ring which may be substituted with 1-3 of substituent(s)) (with the proviso that when the carbocyclic ring of said —O—CH 2 -(carbocyclic ring which may be substituted with 1-3 of substituent(s) is phenyl, said ring is substituted with at least one substituent(s)), —O—(C2-4 alkylene)-(carbocyclic ring which may be substituted with 1-3 of substituent(s)), —O—(C1-4 alkylene)-(heterocyclic ring which may be substituted with 1-3 of substituent(s)), —S—(C1-4 alkylene)-(carbocyclic ring or heterocyclic ring which may be substituted with 1-3 of substituent(s)), —NR 39 -4 alkylene)-(carbocyclic ring or heterocyclic ring which may be substituted with 1-3 substituent(s)) (in which R 39 is hydrogen, C1-4 alkyl which may be substituted with one phenyl or C2-5 acyl which may be substituted with 1-3 of halogen) or —CO-(carbocyclic ring or heterocyclic ring which may be substituted with 1-3 substituent(s)), wherein the substituent(s) of the carboxylic ring and heterocyclic ring in L and M are selected from C1-4 alkyl, C2-4 alkenyl, hydroxy, C1-4 alkoxy, —(C1-4 alkylene)-OH, —O—(C1-4 alkylene)-O—(C1-4 alkyl), halogen, —NR 40 R 41 (in which R 40 and R 41 are independently, hydrogen, C1-4 alkyl or C1-4 alkoxycarbonyl, or R 40 and R 41 taken together with nitrogen atom to which they are attached represents 5-7-membered saturated heterocyclic ring necessarily containing one nitrogen atom and optionally further containing one nitrogen atom or one oxygen atom), SR 42 (in which R 42 is hydrogen or C1-4 alkyl), nitro, trifluoromethyl, C1-4 alkoxycarbonyl, oxo and C2-5 acyl, with the proviso that when J is J 1 , R 4 does not represent R 4-1 , or a pharmaceutically acceptable salt thereof.